A5013065776- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Cancer Cells and Metastasis
- Cancer, Hypoxia, and Metabolism
- Cellular Mechanics and Interactions
- Single-cell and spatial transcriptomics
- Cancer-related Molecular Pathways
- Multiple Myeloma Research and Treatments
- Melanoma and MAPK Pathways
- Hippo pathway signaling and YAP/TAZ
- Ferroptosis and cancer prognosis
- Genetic factors in colorectal cancer
- Ubiquitin and proteasome pathways
Heidelberg University
2020-2022
German Cancer Research Center
2020-2022
National Center for Tumor Diseases
2020-2022
Nationales Centrum für Tumorerkrankungen Dresden
2021
Intra-tumor heterogeneity of tumor-initiating cell (TIC) activity drives colorectal cancer (CRC) progression and therapy resistance. Here, we used single-cell RNA-sequencing patient-derived CRC models to decipher distinct subpopulations based on their transcriptional profiles. Cell type-specific expression modules stem-like, transit amplifying-like, differentiated cells resemble differentiation states normal intestinal epithelial cells. Strikingly, identified differ in proliferative...
The development of secondary resistance (SR) in metastatic colorectal cancer (mCRC) treated with anti-epidermal growth factor receptor (anti-EGFR) antibodies is not fully understood at the molecular level. Here we tested vivo selection anti-EGFR SR tumors CRC patient-derived xenograft (PDX) models as a strategy for dissection mechanisms. We analyzed 21 KRAS, NRAS, BRAF, and PI3K wildtype their sensitivity. Furthermore, 31 were generated via chronic treatment cetuximab. A multi-omics approach...
Abstract Accumulating evidence identifies non-genetic mechanisms substantially contributing to drug resistance in cancer patients. Preclinical and clinical data implicate the transcriptional co-activators YAP1 its paralog TAZ multiple targeted therapies, highlighting strong need for therapeutic strategies overcoming YAP1/TAZ-mediated across tumor entities. Here, we show particularly high YAP1/TAZ activity MITF low /AXL melanomas characterized by MAPK pathway inhibition broad receptor...
Disseminated tumor cells (dTCs) can frequently be detected in the bone marrow (BM) of colorectal cancer (CRC) patients, raising possibility that BM serves as a reservoir for metastatic cells. Identification dTCs aspirates harbors potential assessing therapeutic outcome and directing therapy intensity with limited risk effort. Still, functional prognostic relevance is not fully established. We have previously shown CRC cell clones traced to mice carrying patient‐derived xenografts. However,...
Abstract Tumor progression in colorectal cancer (CRC) is driven by a subpopulation of cells with tumor-initiating cell (TIC) activity. In the past, bulk experiments provided strong evidence for functional heterogeneity CRC TIC compartment distinct types TICs driving progression. However, these retrospective direct assignment states to individual functionally relevant has not been possible. We here asked whether can be assigned specific subpopulations. Therefore, 4,663 single-cell profiles...